Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 8, 2025

WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 8, 2025-- Incyte Corporation (Nasdaq: INCY) announced today that it granted equity inducement awards to Mohamed Issa, the Company's new Executive Vice President, Head of U.S. Oncology, pursuant to the Company's 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company's Board of Directors as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

As an inducement material to his employment and as a make whole grant, Dr. Issa received an award of 48,671 restricted stock units (RSUs) with a grant and vesting commencement date of January 6, 2025, which vest as to 25% of the shares subject to the RSUs on each of the first four anniversaries of the vesting commencement date, subject to his continued service with the Company on each such date. Dr. Issa also will receive, as an inducement material to his employment and as a make whole grant, an award of 27,812 RSUs on June 30, 2025, which will vest as to 25% of the shares subject to the RSUs on each of the first four anniversaries of the vesting commencement date of January 6, 2025, subject to his continued service with the Company on each such date.

About Incyte
A global biopharmaceutical company on a mission to *Solve On.*, Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250108207896/en/

Media
media@incyte.com

Investors
ir@incyte.com

Source: Incyte Corporation